FDA approved point-of-care test, Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test detects both HIV-1/2 antibodies and free HIV-1 p24 antigen on a single test strip.
CLIA-Waived for fingerstick whole blood.
Features for the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test
Built-in quality controls to let you know the test is working.
Test in
Introducing the new standard in HIV point of care testing.
By quickly and accurately identifying HIV positive patients earlier, you can increase case finding and facilitate fast and appropriate linkage to care.
The 4th generation Alere™ HIV Combo test detects more acute infections compared to 2nd and 3rd generation tests. This helps
The enumeration of absolute numbers of T-helper cells (commonly referred to as a CD4 count) has become an essential part of monitoring the course of immunosuppression caused by the Human Immunodeficiency Virus (HIV) and the initiation of Anti-Retroviral Therapy.
The Pima™ CD4 test gives you the ability to monitor patients while
Description
Syphilis is caused by the organism Treponema pallidum and is usually transmitted via sexual contact; it can also be transmitted from mother to child (congenital syphilis). It is curable; left untreated, however, it can lead to irreversible neurological and cardiac damage.
Alere Determine™ Syphilis TP is an in vitro, visually read,
Rapid Rule-in TB-HIV co-infection
The Alere Determine™ TB LAM Ag test empowers you, at the point-of-care, to screen for active TB in HIV positive patients, providing results in just minutes.
This novel rapid test detects the LAM antigen (lipoarabinomannan) in urine samples, assisting you in your TB screening to rule-in sooner than
This simple yet smart assay provides next generation virological HIV-1 and HIV-2 results at the point-of-care within 52 minutes. It’s perfectly suited for the challenges of virological testing in infants and adults in resource limited settings.
Designed to provide actionable results while the patient is still present.
WHO recommends a viral load test at 6 months and 12 months, and annually thereafter if the patient is stable on ART1, but few patients receive that level of care.
UNAIDS 909090 Goal: 90% of patients on
Take the Pima™ CD4 test wherever it is needed using the Pima™ Analyser Bag workstation. Designed specifically to hold the Pima™ Analyser, Pima™ Printer, Pima™ CD4 cartridges as well as sample collection accessories, the Pima™ Analyser Bag is an indispensable accessory for the secure transport of your Analyser from location
Product Description
The Pima™ Printer is a portable thermal printer for the Pima Analyser.
Connected to and powered by the Pima™ Analyser via a USB port, the Pima™ Printer enables printing of Pima™ Test Reports.
Product Description
Pima™ CD4 Cartridges are a breakthrough technology that, in combination with the Pima™ Analyser, help to provide absolute CD4 lymphocyte (T-helper cell) counts within 20 minutes.
